DeepMed Research

Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Non-Resectable Pancreas Carcinoma

Interventions: Drug: Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection

First Posted Date: 2024-05-01

Last Posted Date: 2024-05-01

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 37

Registration Number: NCT06393166

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

GMA-Tulip, I-gel and the LMA-Supreme (LMA-S) Devices in Airway Management

Not Applicable

Recruiting

Conditions: Anesthesia
Airway Remodeling

Interventions: Device: I-gel group
Device: GMA-Tulip
Device: LMA supreme group

First Posted Date: 2024-04-25

Last Posted Date: 2025-04-30

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 498

Registration Number: NCT06383494

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Phase 2

Recruiting

Conditions: HER2 Gene Mutation
Bile Duct Adenocarcinoma Non-Resectable

Interventions: Drug: Disitamab Vedotin Plus Cadonilimab

First Posted Date: 2024-04-25

Last Posted Date: 2024-04-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 28

Registration Number: NCT06383533

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Sintilimab, bevacizumab, gemcitabine
Radiation: IMRT

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT06364826

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Not Applicable

Recruiting

Conditions: Biliary Tract Carcinoma
Hepatocellular Carcinoma
Colorectal Adenocarcinoma
Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma

Interventions: Radiation: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Drug: Anti-PD-1 monoclonal antibody
Drug: Gemcitabine and Cisplatin
Drug: Anti-VEGF 15mg/kg
Drug: Oxaliplatin and Capecitabine
Drug: Anti-VEGF 7.5mg/kg

First Posted Date: 2024-04-05

Last Posted Date: 2024-08-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT06349044

Locations: 🇨🇳
Zhengjiang Cancer Hospital, Hangzhou, Zhejiang, China

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Phase 2

Recruiting

Conditions: Extensive Stage Lung Small Cell Cancer

Interventions: Drug: Serplulimab
Radiation: Chest Radiation

First Posted Date: 2024-04-05

Last Posted Date: 2024-04-05

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT06350162

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin
Drug: Sintilimab

First Posted Date: 2024-03-13

Last Posted Date: 2024-03-13

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 81

Registration Number: NCT06308939

Locations: 🇨🇳
zhejiangCH, Hangzhou, Zhejiang, China

Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Phase 1

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: irinotecan liposomes+capecitabine

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06300489

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

Phase 2

Recruiting

Conditions: Vulvar and Vaginal Cancer

Interventions: Drug: Cardunolizumab

First Posted Date: 2024-03-05

Last Posted Date: 2024-11-21

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT06292689

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Phase 2

Recruiting

Conditions: Adjuvant Radiotherapy

Interventions: Other: Observation
Radiation: Adjuvant radiotherapy

First Posted Date: 2024-02-22

Last Posted Date: 2024-07-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 146

Registration Number: NCT06272214

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy